JP2010534191A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010534191A5 JP2010534191A5 JP2010503072A JP2010503072A JP2010534191A5 JP 2010534191 A5 JP2010534191 A5 JP 2010534191A5 JP 2010503072 A JP2010503072 A JP 2010503072A JP 2010503072 A JP2010503072 A JP 2010503072A JP 2010534191 A5 JP2010534191 A5 JP 2010534191A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- isolated peptide
- item
- antibody
- abcb5
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 91
- 239000000203 mixture Substances 0.000 claims description 39
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 36
- 101000677872 Homo sapiens ATP-binding cassette sub-family B member 5 Proteins 0.000 claims description 31
- 102100021501 ATP-binding cassette sub-family B member 5 Human genes 0.000 claims description 29
- 206010028980 Neoplasm Diseases 0.000 claims description 19
- 201000011510 cancer Diseases 0.000 claims description 19
- 239000000427 antigen Substances 0.000 claims description 16
- 108091007433 antigens Proteins 0.000 claims description 16
- 102000036639 antigens Human genes 0.000 claims description 16
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 14
- 239000012634 fragment Substances 0.000 claims description 14
- 238000006467 substitution reaction Methods 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 229940124597 therapeutic agent Drugs 0.000 claims description 13
- 239000002246 antineoplastic agent Substances 0.000 claims description 7
- 229940127089 cytotoxic agent Drugs 0.000 claims description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 206010070834 Sensitisation Diseases 0.000 claims description 3
- 230000003834 intracellular effect Effects 0.000 claims description 3
- 230000008313 sensitization Effects 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 238000007910 systemic administration Methods 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 2
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 2
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 2
- 108020004459 Small interfering RNA Proteins 0.000 claims description 2
- 102000057984 human ABCB5 Human genes 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 239000002924 silencing RNA Substances 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 238000000034 method Methods 0.000 description 12
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 8
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 8
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 7
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical group C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 7
- 229940127093 camptothecin Drugs 0.000 description 7
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 4
- 238000006471 dimerization reaction Methods 0.000 description 4
- -1 menogalyl Chemical compound 0.000 description 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- OUPZKGBUJRBPGC-HLTSFMKQSA-N 1,5-bis[[(2r)-oxiran-2-yl]methyl]-3-[[(2s)-oxiran-2-yl]methyl]-1,3,5-triazinane-2,4,6-trione Chemical compound O=C1N(C[C@H]2OC2)C(=O)N(C[C@H]2OC2)C(=O)N1C[C@H]1CO1 OUPZKGBUJRBPGC-HLTSFMKQSA-N 0.000 description 1
- AWVHFDOHKFRHKQ-UHFFFAOYSA-N 2-[10-(3-aminopropylimino)-6,8-dihydroxy-3-oxo-14,15-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-1,4,6,8,11,13(16)-hexaen-14-yl]ethyl-(2-hydroxyethyl)azanium chloride Chemical compound C1=CC(=NCCCN)C2=C(C3=C(C=CC(=O)C3=C4C2=C1N(N4)CC[NH2+]CCO)O)O.[Cl-] AWVHFDOHKFRHKQ-UHFFFAOYSA-N 0.000 description 1
- BTQAFTBKHVLPEV-UHFFFAOYSA-N 3h-naphtho[2,3-e]indazole Chemical class C1=CC=CC2=CC3=C4C=NNC4=CC=C3C=C21 BTQAFTBKHVLPEV-UHFFFAOYSA-N 0.000 description 1
- ODACNRQBNVVGAI-UHFFFAOYSA-N 5-[2-chloroethyl(2-fluoroethyl)amino]-6-methyl-1h-pyrimidine-2,4-dione Chemical compound CC=1NC(=O)NC(=O)C=1N(CCF)CCCl ODACNRQBNVVGAI-UHFFFAOYSA-N 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- GOJJWDOZNKBUSR-UHFFFAOYSA-N 7-sulfamoyloxyheptyl sulfamate Chemical compound NS(=O)(=O)OCCCCCCCOS(N)(=O)=O GOJJWDOZNKBUSR-UHFFFAOYSA-N 0.000 description 1
- 241000219198 Brassica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 101100420681 Caenorhabditis elegans tir-1 gene Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 101000994369 Homo sapiens Integrin alpha-5 Proteins 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100032817 Integrin alpha-5 Human genes 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 102000008730 Nestin Human genes 0.000 description 1
- 108010088225 Nestin Proteins 0.000 description 1
- XESARGFCSKSFID-UHFFFAOYSA-N Pyrazofurin Natural products OC1=C(C(=O)N)NN=C1C1C(O)C(O)C(CO)O1 XESARGFCSKSFID-UHFFFAOYSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 102000008790 VE-cadherin Human genes 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- YWCASUPWYFFUHE-UHFFFAOYSA-N bis(3-methylsulfonyloxypropyl)azanium;chloride Chemical compound [Cl-].CS(=O)(=O)OCCC[NH2+]CCCOS(C)(=O)=O YWCASUPWYFFUHE-UHFFFAOYSA-N 0.000 description 1
- 229950008548 bisantrene Drugs 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 108010018828 cadherin 5 Proteins 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-M lysinate Chemical compound NCCCCC(N)C([O-])=O KDXKERNSBIXSRK-UHFFFAOYSA-M 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- NJSMWLQOCQIOPE-OCHFTUDZSA-N n-[(e)-[10-[(e)-(4,5-dihydro-1h-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1h-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 description 1
- 210000005055 nestin Anatomy 0.000 description 1
- JTHRRMFZHSDGNJ-UHFFFAOYSA-N piperazine-2,3-dione Chemical compound O=C1NCCNC1=O JTHRRMFZHSDGNJ-UHFFFAOYSA-N 0.000 description 1
- XESARGFCSKSFID-FLLFQEBCSA-N pirazofurin Chemical compound OC1=C(C(=O)N)NN=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 XESARGFCSKSFID-FLLFQEBCSA-N 0.000 description 1
- 229950008703 teroxirone Drugs 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 1
- 229950001353 tretamine Drugs 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- 229960000641 zorubicin Drugs 0.000 description 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92312807P | 2007-04-12 | 2007-04-12 | |
| US60/923,128 | 2007-04-12 | ||
| US705907P | 2007-12-11 | 2007-12-11 | |
| US61/007,059 | 2007-12-11 | ||
| PCT/US2008/004715 WO2008127656A1 (en) | 2007-04-12 | 2008-04-11 | Targeting abcb5 for cancer therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014090150A Division JP2014133770A (ja) | 2007-04-12 | 2014-04-24 | 癌療法のためのａｂｃｂ５標的化 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010534191A JP2010534191A (ja) | 2010-11-04 |
| JP2010534191A5 true JP2010534191A5 (https=) | 2011-05-06 |
| JP5889527B2 JP5889527B2 (ja) | 2016-03-22 |
Family
ID=39661432
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010503072A Active JP5889527B2 (ja) | 2007-04-12 | 2008-04-11 | 癌療法のためのａｂｃｂ５標的化 |
| JP2014090150A Withdrawn JP2014133770A (ja) | 2007-04-12 | 2014-04-24 | 癌療法のためのａｂｃｂ５標的化 |
| JP2016153402A Active JP6268237B2 (ja) | 2007-04-12 | 2016-08-04 | 癌療法のためのａｂｃｂ５標的化 |
| JP2017247931A Active JP6530044B2 (ja) | 2007-04-12 | 2017-12-25 | 癌療法のためのａｂｃｂ５標的化 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014090150A Withdrawn JP2014133770A (ja) | 2007-04-12 | 2014-04-24 | 癌療法のためのａｂｃｂ５標的化 |
| JP2016153402A Active JP6268237B2 (ja) | 2007-04-12 | 2016-08-04 | 癌療法のためのａｂｃｂ５標的化 |
| JP2017247931A Active JP6530044B2 (ja) | 2007-04-12 | 2017-12-25 | 癌療法のためのａｂｃｂ５標的化 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US7928202B2 (https=) |
| EP (3) | EP2155248B1 (https=) |
| JP (4) | JP5889527B2 (https=) |
| AU (1) | AU2008239633B2 (https=) |
| CA (1) | CA2718573C (https=) |
| CY (2) | CY1116823T1 (https=) |
| DK (2) | DK2644205T3 (https=) |
| ES (2) | ES2547016T3 (https=) |
| HR (2) | HRP20150934T1 (https=) |
| HU (2) | HUE027593T2 (https=) |
| LT (1) | LT2644205T (https=) |
| PL (2) | PL2644205T3 (https=) |
| PT (2) | PT2155248E (https=) |
| SI (2) | SI2155248T1 (https=) |
| WO (1) | WO2008127656A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2411101C (en) | 2000-06-05 | 2018-01-16 | Brigham And Women's Hospital, Inc. | A gene encoding a multidrug resistance human p-glycoprotein homologue on chromosome 7p15-21 and uses thereof |
| SI2772535T1 (sl) | 2006-05-31 | 2022-08-31 | Children's Medical Center Corporation | ABC5 pozitivne mezenhimske matične celice kot imunomodulatorji |
| EP2155248B1 (en) | 2007-04-12 | 2015-06-10 | The Brigham and Women's Hospital, Inc. | Targeting abcb5 for cancer therapy |
| US11542328B2 (en) | 2008-11-14 | 2023-01-03 | The Brigham And Women's Hospital, Inc. | Therapeutic and diagnostic methods relating to cancer stem cells |
| EP3978928A1 (en) * | 2008-11-14 | 2022-04-06 | The Brigham and Women's Hospital, Inc. | Therapeutic and diagnostic methods relating to cancer stem cells |
| WO2010065711A1 (en) * | 2008-12-04 | 2010-06-10 | Adimab, Inc. | An abcb5 epitope and antibodies thereto for the treatment of cancer |
| US20110280862A1 (en) * | 2010-05-14 | 2011-11-17 | The University Of Hong Kong | Gep and drug transporter regulation, cancer therapy and prognosis |
| WO2014130518A1 (en) | 2013-02-19 | 2014-08-28 | Children's Medical Center Corporation | Abcb5(+) stem cells for treating ocular disease |
| AU2014262590B2 (en) | 2013-05-10 | 2018-05-10 | Children's Medical Center Corporation | Wound healing and tissue engineering |
| US9177410B2 (en) | 2013-08-09 | 2015-11-03 | Ayla Mandel | System and method for creating avatars or animated sequences using human body features extracted from a still image |
| WO2016179576A1 (en) * | 2015-05-07 | 2016-11-10 | Bioxcel Corporation | Novel immunomodulatory therapeutic strategies targeting tumors in cancer |
| CN116059219A (zh) | 2015-07-16 | 2023-05-05 | 比奥克斯塞尔医疗股份有限公司 | 一种使用免疫调节治疗癌症的新颖方法 |
| MX2020011297A (es) * | 2018-04-25 | 2020-11-18 | Childrens Medical Center | Ligandos y substratos de abcb5. |
| US12014835B2 (en) | 2020-02-19 | 2024-06-18 | Vanderbilt University | Methods for evaluating therapeutic benefit of combination therapies |
| CN115835882A (zh) * | 2020-04-15 | 2023-03-21 | 儿童医学中心公司 | 靶向多形性胶质母细胞瘤中的abcb5 |
| AU2021262864A1 (en) * | 2020-04-30 | 2022-11-17 | Children's Medical Center Corporation | Antibodies specific to ABCB5 and uses thereof |
| CN116836291B (zh) * | 2023-08-25 | 2023-11-07 | 宝船生物医药科技(上海)有限公司 | 抗cd47-cldn18.2双特异性抗体的抗独特型抗体及其制备方法和应用 |
Family Cites Families (105)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US565354A (en) | 1896-08-04 | James h | ||
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| WO1980001139A1 (en) | 1978-12-06 | 1980-06-12 | Svedman Paul | Device for treating tissues,for example skin |
| US4355023A (en) | 1980-09-30 | 1982-10-19 | The Massachusetts General Hospital | Antibody fragment compositions and process |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4470925A (en) | 1982-05-05 | 1984-09-11 | E. I. Du Pont De Nemours And Company | Immunoglobulin half-molecules and process for producing hybrid antibodies |
| US4462334A (en) | 1982-08-19 | 1984-07-31 | Kim Ho K | Solar animal structure |
| AT379688B (de) | 1982-11-22 | 1986-02-10 | List Hans | Sensorelement zur bestimmung des o2-gehaltes einer probe |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| DE3587465T2 (de) | 1984-09-10 | 1994-01-20 | Hsc Res Dev Corp | Vielfache Drogen-Resistenz in Säugetierzellinien und Isolierung der determinanten Glykoprotein-DNS. |
| US4837306A (en) | 1985-02-25 | 1989-06-06 | The Ontario Cancer Institute | Method for selecting hybridomas producing antibodies specific to the P-glycoprotein cell suface antigen and a cDNA clone encoding the C-terminal portion of the antigen |
| GB8509978D0 (en) | 1985-04-18 | 1985-05-30 | Juhasz L | Wound dressings |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US5565354A (en) | 1986-09-05 | 1996-10-15 | Sandoz Ltd. | Production of human monoclonal antibodies specific for hepatitis B surface antigen |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5053394A (en) | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
| US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| AU632065B2 (en) | 1988-09-23 | 1992-12-17 | Novartis Vaccines And Diagnostics, Inc. | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5211657A (en) | 1988-11-07 | 1993-05-18 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5399483A (en) | 1989-03-30 | 1995-03-21 | Suntory Limited | Expression of MDR-related gene in yeast cell |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| US5434075A (en) | 1992-03-20 | 1995-07-18 | Board Of Trustees Of The University Of Illinois | Monoclonal antibody to a human MDR1 multidrug resistance gene product, and uses |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| DE69232137T2 (de) | 1991-11-25 | 2002-05-29 | Enzon Inc | Multivalente antigen-bindende proteine |
| US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
| US6436078B1 (en) | 1994-12-06 | 2002-08-20 | Pal Svedman | Transdermal perfusion of fluids |
| ATE244763T1 (de) | 1992-02-11 | 2003-07-15 | Cell Genesys Inc | Erzielen von homozygotem durch zielgerichtete genetische ereignisse |
| US6231881B1 (en) | 1992-02-24 | 2001-05-15 | Anton-Lewis Usala | Medium and matrix for long-term proliferation of cells |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| IT1257893B (it) | 1992-06-17 | 1996-02-16 | Ist Superiore Sanita | Anticorpi monoclonali che riconoscono un epitopo della p-glicoproteina umana. |
| MD1367C2 (ro) | 1992-11-13 | 2000-11-30 | Idec Pharmaceuticals Corporation | Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom. |
| GB2272645B8 (en) | 1992-11-23 | 2010-02-10 | Johnson & Johnson Medical | Wound dressing |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| WO1995018972A1 (en) | 1994-01-05 | 1995-07-13 | Arqule, Inc. | Systematic modular production of aminimide- and oxazolone-based molecules having selected properties |
| GB9403135D0 (en) | 1994-02-18 | 1994-04-06 | Univ Glasgow | Wound healing device |
| EP0804249A2 (en) | 1994-03-15 | 1997-11-05 | Brown University Research Foundation | Polymeric gene delivery system |
| US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5686578A (en) * | 1994-08-05 | 1997-11-11 | Immunomedics, Inc. | Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype |
| US5712171A (en) | 1995-01-20 | 1998-01-27 | Arqule, Inc. | Method of generating a plurality of chemical compounds in a spatially arranged array |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| JP3403416B2 (ja) * | 1996-06-28 | 2003-05-06 | 松下電工株式会社 | 改質装置 |
| US5904659A (en) | 1997-02-14 | 1999-05-18 | Exogen, Inc. | Ultrasonic treatment for wounds |
| US6152142A (en) | 1997-02-28 | 2000-11-28 | Tseng; Scheffer C. G. | Grafts made from amniotic membrane; methods of separating, preserving, and using such grafts in surgeries |
| DE19722075C1 (de) | 1997-05-27 | 1998-10-01 | Wilhelm Dr Med Fleischmann | Vorrichtung zur Applikation von Wirkstoffen an einer Wundoberfläche |
| US6420622B1 (en) | 1997-08-01 | 2002-07-16 | 3M Innovative Properties Company | Medical article having fluid control film |
| US6071267A (en) | 1998-02-06 | 2000-06-06 | Kinetic Concepts, Inc. | Medical patient fluid management interface system and method |
| ES2292236T3 (es) | 1998-04-02 | 2008-03-01 | Genentech, Inc. | Variantes de anticuerpos y sus fragmentos. |
| GB9808836D0 (en) | 1998-04-27 | 1998-06-24 | Amersham Pharm Biotech Uk Ltd | Microfabricated apparatus for cell based assays |
| JP4220058B2 (ja) | 1998-06-30 | 2009-02-04 | 浜松ホトニクス株式会社 | 半導体位置検出器 |
| US6479072B1 (en) | 1999-02-11 | 2002-11-12 | The General Hospital Corporation | Microfabricated membranes and matrices |
| US6277574B1 (en) | 1999-04-09 | 2001-08-21 | Incyte Genomics, Inc. | Genes associated with diseases of the kidney |
| DE60039451D1 (de) | 1999-11-29 | 2008-08-21 | Hill Rom Services Inc | Vorrichtung zur behandlung einer wunde |
| PT1309726E (pt) | 2000-03-30 | 2010-03-08 | Whitehead Biomedical Inst | Mediadores de interferência por rna específicos de sequência de rna |
| CA2411101C (en) | 2000-06-05 | 2018-01-16 | Brigham And Women's Hospital, Inc. | A gene encoding a multidrug resistance human p-glycoprotein homologue on chromosome 7p15-21 and uses thereof |
| WO2001096361A1 (en) * | 2000-06-12 | 2001-12-20 | University Of Maryland Biotechnology Institute | Method of controlling the binding of calmyrin to presenilin |
| ATE446366T1 (de) | 2000-06-22 | 2009-11-15 | Genentech Inc | Agonistische monoklonale antikörper gegen trkc |
| EP1322936A2 (en) | 2000-10-03 | 2003-07-02 | California Institute Of Technology | Microfluidic devices and methods of use |
| JP2004531213A (ja) | 2000-10-27 | 2004-10-14 | インサイト・ゲノミックス・インコーポレイテッド | 輸送体及びイオンチャネル |
| US6855135B2 (en) | 2000-11-29 | 2005-02-15 | Hill-Rom Services, Inc. | Vacuum therapy and cleansing dressing for wounds |
| US6685681B2 (en) | 2000-11-29 | 2004-02-03 | Hill-Rom Services, Inc. | Vacuum therapy and cleansing dressing for wounds |
| US8015677B2 (en) | 2000-12-01 | 2011-09-13 | Aard-Balm Limited | Embalming fluid |
| US6767194B2 (en) | 2001-01-08 | 2004-07-27 | President And Fellows Of Harvard College | Valves and pumps for microfluidic systems and method for making microfluidic systems |
| WO2002062968A2 (en) | 2001-02-02 | 2002-08-15 | The Regents Of The University Of Michigan | Micro-tubular materials and cell constructs |
| WO2002083046A1 (en) | 2001-04-16 | 2002-10-24 | Pamela Howard | Wound dressing system |
| EP1461113A4 (en) | 2001-12-26 | 2009-05-06 | Hill Rom Services Inc | ASSOCIATION SET FOR WOUND VACUUM THERAPY |
| WO2003057070A2 (en) | 2001-12-26 | 2003-07-17 | Hill-Rom Services Inc. | Vented vacuum bandage and method |
| US8034904B2 (en) | 2002-06-14 | 2011-10-11 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| CA2491017A1 (en) | 2002-07-03 | 2004-01-15 | Immunogen, Inc. | Antibodies to non-shed muc1 and muc16, and uses thereof |
| ES2350687T3 (es) | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
| BR0316101A (pt) | 2002-11-07 | 2005-09-27 | Immunogen Inc | Anticorpos anticd33 e processo para tratamento de leucemia melóide aguda usando os mesmos |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| EP1639090A4 (en) | 2003-06-09 | 2008-04-16 | Univ Michigan | COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER |
| GB0325130D0 (en) | 2003-10-28 | 2003-12-03 | Smith & Nephew | Apparatus with scaffold |
| EP1702061A4 (en) | 2003-11-24 | 2007-05-02 | Univ Rockefeller | METHOD OF INSULATING A SELF-RENEWING, MULTIPOTENTIAL, SLOWLY CIRCULATING CELL |
| DK2311873T3 (en) | 2004-01-07 | 2018-11-26 | Novartis Vaccines & Diagnostics Inc | M-CSF-SPECIFIC MONOCLONAL ANTIBODY AND APPLICATIONS THEREOF |
| US7364592B2 (en) | 2004-02-12 | 2008-04-29 | Dexcom, Inc. | Biointerface membrane with macro-and micro-architecture |
| GB0416168D0 (en) * | 2004-07-20 | 2004-08-18 | Vernalis Cambridge Ltd | Pyrmidothiophene compounds |
| CA3218940A1 (en) | 2004-11-12 | 2006-05-18 | Cambridge University Technical Services Ltd. | Methods and means related to cancer stem cells |
| WO2006135886A2 (en) | 2005-06-13 | 2006-12-21 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| EP1907858A4 (en) | 2005-06-13 | 2009-04-08 | Univ Michigan | COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER |
| SI2772535T1 (sl) | 2006-05-31 | 2022-08-31 | Children's Medical Center Corporation | ABC5 pozitivne mezenhimske matične celice kot imunomodulatorji |
| WO2008030616A2 (en) | 2006-09-07 | 2008-03-13 | Stemline Therapeutics, Inc. | Monitoring cancer stem cells |
| EP2155248B1 (en) | 2007-04-12 | 2015-06-10 | The Brigham and Women's Hospital, Inc. | Targeting abcb5 for cancer therapy |
| EP3978928A1 (en) | 2008-11-14 | 2022-04-06 | The Brigham and Women's Hospital, Inc. | Therapeutic and diagnostic methods relating to cancer stem cells |
| WO2014130518A1 (en) | 2013-02-19 | 2014-08-28 | Children's Medical Center Corporation | Abcb5(+) stem cells for treating ocular disease |
| AU2014262590B2 (en) | 2013-05-10 | 2018-05-10 | Children's Medical Center Corporation | Wound healing and tissue engineering |
-
2008
- 2008-04-11 EP EP08742787.8A patent/EP2155248B1/en active Active
- 2008-04-11 PT PT87427878T patent/PT2155248E/pt unknown
- 2008-04-11 PL PL13163810T patent/PL2644205T3/pl unknown
- 2008-04-11 ES ES08742787.8T patent/ES2547016T3/es active Active
- 2008-04-11 SI SI200831496T patent/SI2155248T1/sl unknown
- 2008-04-11 LT LTEP13163810.8T patent/LT2644205T/lt unknown
- 2008-04-11 US US12/101,428 patent/US7928202B2/en active Active
- 2008-04-11 AU AU2008239633A patent/AU2008239633B2/en active Active
- 2008-04-11 SI SI200831993T patent/SI2644205T1/sl unknown
- 2008-04-11 PL PL08742787T patent/PL2155248T3/pl unknown
- 2008-04-11 DK DK13163810.8T patent/DK2644205T3/en active
- 2008-04-11 WO PCT/US2008/004715 patent/WO2008127656A1/en not_active Ceased
- 2008-04-11 DK DK08742787.8T patent/DK2155248T3/en active
- 2008-04-11 EP EP18177392.0A patent/EP3431103B1/en active Active
- 2008-04-11 JP JP2010503072A patent/JP5889527B2/ja active Active
- 2008-04-11 ES ES13163810.8T patent/ES2687270T3/es active Active
- 2008-04-11 EP EP13163810.8A patent/EP2644205B1/en active Active
- 2008-04-11 HR HRP20150934TT patent/HRP20150934T1/hr unknown
- 2008-04-11 HU HUE08742787A patent/HUE027593T2/en unknown
- 2008-04-11 CA CA2718573A patent/CA2718573C/en active Active
- 2008-04-11 HU HUE13163810A patent/HUE039385T2/hu unknown
- 2008-04-11 PT PT13163810T patent/PT2644205T/pt unknown
-
2011
- 2011-03-10 US US13/044,854 patent/US8697072B2/en active Active
-
2014
- 2014-04-14 US US14/251,932 patent/US9266946B2/en active Active
- 2014-04-24 JP JP2014090150A patent/JP2014133770A/ja not_active Withdrawn
-
2015
- 2015-09-10 CY CY20151100784T patent/CY1116823T1/el unknown
-
2016
- 2016-01-25 US US15/005,364 patent/US9855342B2/en active Active
- 2016-08-04 JP JP2016153402A patent/JP6268237B2/ja active Active
-
2017
- 2017-12-25 JP JP2017247931A patent/JP6530044B2/ja active Active
-
2018
- 2018-08-28 HR HRP20181385TT patent/HRP20181385T1/hr unknown
- 2018-09-12 CY CY181100944T patent/CY1121046T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010534191A5 (https=) | ||
| CN108136012B (zh) | 靶向分子的抗原结合构建体 | |
| CN105017420B (zh) | 针对整联蛋白αvβ6的抗体和使用该抗体治疗癌症 | |
| CN115052893A (zh) | 抗tigit抗体和使用方法 | |
| JP2021503455A5 (https=) | ||
| US20220010018A1 (en) | MONOCLONAL ANTIBODIES AGAINST IgV DOMAIN OF B7-H3 AND USES THEREOF | |
| HRP20120701T1 (hr) | Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1 | |
| CN112074538B (zh) | 结合her2和/或aplp2的抗体和双特异性抗原结合分子、其缀合物和用途 | |
| JP2018520092A5 (https=) | ||
| JP2020058359A5 (https=) | ||
| RU2013125306A (ru) | Связывающие протеины, специфичные по отношению к инсулин-подобным факторам роста, и их использование | |
| CN111491661B (zh) | M(h)dm2/4的抗体及其在诊断和治疗癌症中的用途 | |
| TW202146456A (zh) | 抗ｃｄ７１抗體類、可活化之抗ｃｄ７１抗體類及使用彼等之方法 | |
| JPWO2020014482A5 (https=) | ||
| CN106255703A (zh) | 抗组织因子单克隆抗体 | |
| JP2010509931A (ja) | 新規抗増殖性化合物 | |
| JP2019512207A5 (https=) | ||
| FI3765525T3 (fi) | Biparatooppisen her2-vasta-aineen ja lääkkeen konjugaatteja ja käyttömenetelmiä | |
| CN113853388A (zh) | 抗-egfrviii抗体及其抗原结合片段 | |
| WO2012057315A1 (ja) | 高い親和性を有する抗cdh3抗体 | |
| CA3235789A1 (en) | Cancer specific plectin-1 specific antibodies and methods of use thereof | |
| CN120712286A (zh) | 抗体、抗原结合片段和使用方法 | |
| JP2016529213A5 (https=) | ||
| US20230312742A1 (en) | CD38 antibodies for the treatment of human diseases | |
| JP2021518748A5 (https=) |